Fusion protein binding to cd47 protein and application thereof
AssigneesHangzhou Sumgen Biotech Co., Ltd., Sumgen Mab (Beijing) Biotech Co., Ltd.
InventorsMing LV, Xiaoran DING, Shiwei MIAO, Bin TAN, Xuegong WANG
Life of this patent
Estimating the term…
Abstract
Provided by the present invention are a fusion protein binding to a CD47 protein and an application thereof, wherein the fusion protein is capable of binding to a CD47 protein by using a KD value of 1×10−8M or lower. The fusion protein may specifically block the interaction between a CD47 protein and SIRPα without causing a blood coagulation reaction, and may further inhibit the growth and/or proliferation of tumors or tumor cells.
Claims27
A fusion protein which specifically binds to a CD47 protein and has at least one of the following characteristics:
- (a) binding to the CD47 protein with a KD value of 1×10−8 M or lower;
- (b) specifically blocking an interaction between the CD47 protein and SIRPα;
- (c) not causing a blood clotting reaction;
- and
- (d) inhibiting the growth and/or proliferation of tumors or tumor cells.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.